Analyst Price Targets — OCGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 23, 2022 4:46 am | Uy Ear | Mizuho Securities | $5.00 | $2.34 | TheFly | Ocugen initiated with a Buy at Mizuho |
| August 15, 2022 11:41 am | — | H.C. Wainwright | $6.00 | $2.88 | Benzinga | HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $6 |
| June 18, 2022 2:00 pm | Jennifer Kim | Cantor Fitzgerald | $4.50 | $2.16 | Pulse 2.0 | Ocugen (OCGN) Stock Price: $4.50 Target And Overweight Rating |
| May 8, 2022 9:16 am | Daniil Gataulin | Chardan Capital | $3.50 | $2.16 | TheFly | Chardan keeps Neutral on Ocugen, lowers price target to $3.50 |
| April 25, 2022 2:12 am | Zegbeh Jallah | Roth Capital | $6.00 | $2.40 | Pulse 2.0 | Ocugen (OCGN) Stock: $6 Price Target And Buy Rating |
Latest News for OCGN
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OCGN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.